Neuronetics posts earnings beat, revenue exceeds forecasts
Medical device maker Neuronetics reported adjusted earnings per share above estimates, with revenue also surpassing projections despite broader sector challenges.
Neuronetics reported adjusted earnings per share of $0.12 for the quarter, beating analyst estimates by $0.07, while revenue reached $28.5 million, exceeding forecasts by $2.1 million.
The company, which specializes in transcranial magnetic stimulation devices for treating major depressive disorder, attributed the outperformance to increased adoption of its NeuroStar Advanced Therapy system. Revenue growth was driven by both domestic and international markets, with a notable rise in patient referrals.
Neuronetics maintained its full-year guidance, forecasting revenue between $110 million and $115 million, alongside adjusted earnings per share in the range of $0.45 to $0.55. The guidance reflects confidence in sustained demand for its mental health treatment solutions amid ongoing economic uncertainties.
Analysts noted the company's ability to navigate a competitive landscape while expanding its market reach. Shares were up 4% in pre-market trading following the results, indicating investor approval of the financial performance.
The earnings report follows a period of heightened scrutiny for medical device companies, with investors closely monitoring operational efficiency and revenue resilience.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →